Another histone modifier, SMYD2 (SET and MYND domain containing 2), a histone methyltransferase, enhances cell vitality in clear cell ovarian carcinoma through ER methylation, whereas inhibiting SMYD2 induces apoptosis in these cancer cells.103. This evidence concerns the gene SMYD2 and ovarian clear cell cancer.